Suppr超能文献

评估联合治疗对中性粒细胞减少的儿科癌症患者革兰氏阴性感染的理论疗效:来自调查数据统计分析的见解。

Assessing the Theoretical Efficacy of Combination Therapy Against Gram-Negative Infections in Neutropenic Pediatric Cancer Patients: Insights from the Statistical Analysis of Survey Data.

作者信息

Castagnola Elio, Bagnasco Francesca, Mesini Alessio, Agyeman Philipp K A, Ammann Roland A, Arrabito Marta, Carlesse Fabianne, D'Amico Maria Rosaria, Giagnuolo Giovanna, Haeusler Gabrielle M, Idelevich Evgeny A, Koenig Christa, Lehrnbecher Thomas, Luckowitsch Marie, Meli Mariaclaudia, Menna Giuseppe, Russo Giovanna, Santolaya de Pablo Maria Elena, Simon Arne, Solopova Galina, Sung Lillian, Tondo Annalisa, Groll Andreas H

机构信息

Infectious Diseases Unit, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.

Epidemiology and Biostatistics Unit, Scientific Directorate, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.

出版信息

Antibiotics (Basel). 2024 Dec 2;13(12):1160. doi: 10.3390/antibiotics13121160.

Abstract

: Empirical antibacterial therapy for febrile neutropenia reduces mortality due to Gram-negative blood stream infections (BSIs). Pediatric guidelines recommend monotherapy with an antipseudomonal beta-lactam or a carbapenem and to add a second anti-Gram-negative agent in selected situations. We evaluated the changes in the proportions of resistance of beta-lactam monotherapies vs. their combination with amikacin, and the possible impact on ICU admission or death. : 797 BSIs due to Gram-negative bacteria in 685 patients were included. Combination therapies with amikacin had a lower percentage of isolates resistant to one or to both drugs compared with the respective monotherapy. The highest OR for ICU admission was observed when both drugs of the combination of meropenem-amikacin were resistant. Mortality was significantly associated with relapse or the progression of the underlying malignancy, and resistance to both drugs of the combinations of cefepime-amikacin or meropenem-amikacin. : This study was based on data collected for a large multinational study, in which the susceptibility of Gram-negative bloodstream isolates was categorized following either EUCAST or CLSI according to local laboratory standards. An escalation antibiogram was generated for each selected drug. For resistant bacteria, the conditional susceptibility probability on resistance was calculated. : In pediatric cancer patients with Gram-negative BSIs, the proportion of the resistant organism correlates with ICU admission or death, which may be reduced by combination therapy. In patients with suspected or confirmed Gram-negative BSIs that are not-improving or deteriorating under monotherapy, escalation to meropenem may represent the best option. Amikacin should be preferred when combination therapy is considered with ciprofloxacin as an alternative in the case of impaired renal function.

摘要

发热性中性粒细胞减少症的经验性抗菌治疗可降低革兰氏阴性血流感染(BSIs)所致的死亡率。儿科指南推荐使用抗假单胞菌β-内酰胺类药物或碳青霉烯类药物进行单药治疗,并在特定情况下加用第二种抗革兰氏阴性菌药物。我们评估了β-内酰胺类单药治疗及其与阿米卡星联合治疗的耐药比例变化,以及对入住重症监护病房(ICU)或死亡的可能影响。:纳入了685例患者的797例革兰氏阴性菌血流感染病例。与各自的单药治疗相比,阿米卡星联合治疗中对一种或两种药物耐药的分离株百分比更低。当美罗培南-阿米卡星联合治疗的两种药物均耐药时,观察到入住ICU的最高比值比。死亡率与潜在恶性肿瘤的复发或进展以及头孢吡肟-阿米卡星或美罗培南-阿米卡星联合治疗中两种药物的耐药显著相关。:本研究基于一项大型跨国研究收集的数据,其中革兰氏阴性血流分离株的药敏按照当地实验室标准根据欧洲药敏试验委员会(EUCAST)或美国临床和实验室标准协会(CLSI)进行分类。为每种选定药物生成了升级抗菌谱。对于耐药菌,计算了耐药条件下的药敏概率。:在患有革兰氏阴性血流感染的儿科癌症患者中,耐药菌比例与入住ICU或死亡相关,联合治疗可能会降低这一比例。在单药治疗下疑似或确诊的革兰氏阴性血流感染患者病情无改善或恶化时,升级为美罗培南可能是最佳选择。在考虑联合治疗时,若肾功能受损,应以阿米卡星为首选,环丙沙星可作为替代药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6843/11672620/e8c33f3279bc/antibiotics-13-01160-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验